Table of Contents
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information Or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
1.4.2. Regional Analysis
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing Prevalence of Genetic Diseases
3.2.1.2. Technological Advancements in Sequencing Platforms and Data Analysis Tools
3.2.1.3. Decreasing Costs of Sequencing
3.2.2. Market Restraint Analysis
3.2.2.1. High Complexity and Costs Associated with Data Storage, Interpretation & Analysis
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Whole Exome Sequencing Market: Product Movement Analysis
4.2. Instruments
4.2.1. Instruments Market, 2018 – 2030 (USD Million)
4.3. Consumables
4.3.1. Consumables Market, 2018 – 2030 (USD Million)
4.4. Services
4.4.1. Services Market, 2018 – 2030 (USD Million)
Chapter 5. Technology Business Analysis
5.1. Whole Exome Sequencing Market: Technology Movement Analysis
5.2. Sequencing by Synthesis
5.2.1. Sequencing By Synthesis Market, 2018 – 2030 (USD Million)
5.3. ION Semiconductor Sequencing
5.3.1. ION Semiconductor Sequencing Market, 2018 – 2030 (USD Million)
5.4. Others
5.4.1. Other Technology Market, 2018 – 2030 (USD Million)
Chapter 6. Workflow Business Analysis
6.1. Whole Exome Sequencing Market: Workflow Movement Analysis
6.2. Pre-Sequencing
6.2.1. Pre-Sequencing Market, 2018 – 2030 (USD Million)
6.3. Sequencing
6.3.1. Sequencing Market, 2018 – 2030 (USD Million)
6.4. Data Analysis
6.4.1. Data Analysis Workflow Market, 2018 – 2030 (USD Million)
Chapter 7. Application Business Analysis
7.1. Clinical Diagnostics
7.1.1. Clinical Diagnostics Market, 2018 – 2030 (USD Million)
7.2. Drug Discovery & Development
7.2.1. Drug Discovery & Development Market, 2018 – 2030 (USD Million)
7.3. Personalized Medicines
7.3.1. Personalized Medicines Market, 2018 – 2030 (USD Million)
7.4. Others
7.4.1. Other Application Market, 2018 – 2030 (USD Million)
Chapter 8. End-Use Business Analysis
8.1. Academic And Research Institutes
8.1.1. Academic And Research Institutes Market, 2018 – 2030 (USD Million)
8.2. Hospitals & Clinics
8.2.1. Hospitals & Clinics Market, 2018 – 2030 (USD Million)
8.3. Pharmaceutical & Biotechnology Companies
8.3.1. Pharmaceutical & Biotechnology Companies Market, 2018 – 2030 (USD Million)
8.4. Others
8.4.1. Other End-use Market, 2018 – 2030 (USD Million)
Chapter 9. Regional Business Analysis
9.1. Whole Exome Sequencing Market Share By Region, 2022 & 2030
9.2. North America
9.2.1. SWOT Analysis
9.2.2. North America Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.2.3. U.S.
9.2.3.1. Key Country Dynamics
9.2.3.2. Target Disease Prevalence
9.2.3.3. Competitive Scenario
9.2.3.4. Regulatory Framework
9.2.3.5. U.S. Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.2.4. Canada
9.2.4.1. Key Country Dynamics
9.2.4.2. Target Disease Prevalence
9.2.4.3. Competitive Scenario
9.2.4.4. Regulatory Framework
9.2.4.5. Canada Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.3. Europe
9.3.1. SWOT Analysis
9.3.2. Europe Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.3.3. UK
9.3.3.1. Key Country Dynamics
9.3.3.2. Target Disease Prevalence
9.3.3.3. Competitive Scenario
9.3.3.4. Regulatory Framework
9.3.3.5. UK Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.3.4. Germany
9.3.4.1. Key Country Dynamics
9.3.4.2. Target Disease Prevalence
9.3.4.3. Competitive Scenario
9.3.4.4. Regulatory Framework
9.3.4.5. Germany Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.3.5. France
9.3.5.1. Key Country Dynamics
9.3.5.2. Target Disease Prevalence
9.3.5.3. Competitive Scenario
9.3.5.4. Regulatory Framework
9.3.5.5. France Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.3.6. Italy
9.3.6.1. Key Country Dynamics
9.3.6.2. Target Disease Prevalence
9.3.6.3. Competitive Scenario
9.3.6.4. Regulatory Framework
9.3.6.5. Italy Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.3.7. Spain
9.3.7.1. Key Country Dynamics
9.3.7.2. Target Disease Prevalence
9.3.7.3. Competitive Scenario
9.3.7.4. Regulatory Framework
9.3.7.5. Spain Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.3.8. Denmark
9.3.8.1. Key Country Dynamics
9.3.8.2. Target Disease Prevalence
9.3.8.3. Competitive Scenario
9.3.8.4. Regulatory Framework
9.3.8.5. Denmark Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.3.9. Sweden
9.3.9.1. Key Country Dynamics
9.3.9.2. Target Disease Prevalence
9.3.9.3. Competitive Scenario
9.3.9.4. Regulatory Framework
9.3.9.5. Sweden Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.3.10. Norway
9.3.10.1. Key Country Dynamics
9.3.10.2. Target Disease Prevalence
9.3.10.3. Competitive Scenario
9.3.10.4. Regulatory Framework
9.3.10.5. Norway Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.4. Asia Pacific
9.4.1. SWOT Analysis
9.4.2. Asia Pacific Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.4.3. Japan
9.4.3.1. Key Country Dynamics
9.4.3.2. Target Disease Prevalence
9.4.3.3. Competitive Scenario
9.4.3.4. Regulatory Framework
9.4.3.5. Japan Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.4.4. China
9.4.4.1. Key Country Dynamics
9.4.4.2. Target Disease Prevalence
9.4.4.3. Competitive Scenario
9.4.4.4. Regulatory Framework
9.4.4.5. China Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.4.5. India
9.4.5.1. Key Country Dynamics
9.4.5.2. Target Disease Prevalence
9.4.5.3. Competitive Scenario
9.4.5.4. Regulatory Framework
9.4.5.5. India Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.4.6. Australia
9.4.6.1. Key Country Dynamics
9.4.6.2. Target Disease Prevalence
9.4.6.3. Competitive Scenario
9.4.6.4. Regulatory Framework
9.4.6.5. Australia Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.4.7. Thailand
9.4.7.1. Key Country Dynamics
9.4.7.2. Target Disease Prevalence
9.4.7.3. Competitive Scenario
9.4.7.4. Regulatory Framework
9.4.7.5. Thailand Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.4.8. South Korea
9.4.8.1. Key Country Dynamics
9.4.8.2. Target Disease Prevalence
9.4.8.3. Competitive Scenario
9.4.8.4. Regulatory Framework
9.4.8.5. South Korea Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.5. Latin America
9.5.1. SWOT Analysis
9.5.2. Latin America Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.5.3. Brazil
9.5.3.1. Key Country Dynamics
9.5.3.2. Target Disease Prevalence
9.5.3.3. Competitive Scenario
9.5.3.4. Regulatory Framework
9.5.3.5. Brazil Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.5.4. Mexico
9.5.4.1. Key Country Dynamics
9.5.4.2. Target Disease Prevalence
9.5.4.3. Competitive Scenario
9.5.4.4. Regulatory Framework
9.5.4.5. Mexico Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.5.5. Argentina
9.5.5.1. Key Country Dynamics
9.5.5.2. Target Disease Prevalence
9.5.5.3. Competitive Scenario
9.5.5.4. Regulatory Framework
9.5.5.5. Argentina Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.6. MEA
9.6.1. SWOT Analysis
9.6.2. MEA Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.6.3. South Africa
9.6.3.1. Key Country Dynamics
9.6.3.2. Target Disease Prevalence
9.6.3.3. Competitive Scenario
9.6.3.4. Regulatory Framework
9.6.3.5. South Africa Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.6.4. Saudi Arabia
9.6.4.1. Key Country Dynamics
9.6.4.2. Target Disease Prevalence
9.6.4.3. Competitive Scenario
9.6.4.4. Regulatory Framework
9.6.4.5. Saudi Arabia Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.6.5. UAE
9.6.5.1. Key Country Dynamics
9.6.5.2. Target Disease Prevalence
9.6.5.3. Competitive Scenario
9.6.5.4. Regulatory Framework
9.6.5.5. UAE Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
9.6.6. Kuwait
9.6.6.1. Key Country Dynamics
9.6.6.2. Target Disease Prevalence
9.6.6.3. Competitive Scenario
9.6.6.4. Regulatory Framework
9.6.6.5. Kuwait Whole Exome Sequencing Market, 2018 – 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Strategy Mapping
10.3. Company Market Share Analysis, 2022
10.4. Company Profiles/Listing
10.4.1. Thermo Fisher Scientific, Inc.
10.4.1.1. Overview
10.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.1.3. Product Benchmarking
10.4.1.4. Strategic Initiatives
10.4.2. Illumina, Inc.
10.4.2.1. Overview
10.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.2.3. Product Benchmarking
10.4.2.4. Strategic Initiatives
10.4.3. Agilent Technologies, Inc
10.4.3.1. Overview
10.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.3.3. Product Benchmarking
10.4.3.4. Strategic Initiatives
10.4.4. BGI
10.4.4.1. Overview
10.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.4.3. Product Benchmarking
10.4.4.4. Strategic Initiatives
10.4.5. PacBio
10.4.5.1. Overview
10.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.5.3. Product Benchmarking
10.4.5.4. Strategic Initiatives
10.4.6. Oxford Nanopore Technologies plc.
10.4.6.1. Overview
10.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.6.3. Product Benchmarking
10.4.6.4. Strategic Initiatives
10.4.7. Azenta US Inc. (GENEWIZ)
10.4.7.1. Overview
10.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.7.3. Product Benchmarking
10.4.7.4. Strategic Initiatives
10.4.8. CD Genomics
10.4.8.1. Overview
10.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.8.3. Product Benchmarking
10.4.8.4. Strategic Initiatives
10.4.9. Novogene Co, Ltd
10.4.9.1. Overview
10.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.9.3. Product Benchmarking
10.4.9.4. Strategic Initiatives
10.4.10. Eurofins Genomics
10.4.10.1. Overview
10.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
10.4.10.3. Product Benchmarking
10.4.10.4. Strategic Initiatives
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/